News
-
According to Pulmatrix, the FDA has granted orphan drug status to the company’s PUR1900 itraconazole DPI for the treatment of fungal lung infections in cystic fibrosis patients, with the FDA stating, “Your designation is based… Read more . . .
-
Molex, which describes itself as “a global manufacturer of complete interconnect solutions,” will acquire device developer and manufacturer Phillips-Medisize from Golden Gate Capital, the company said. The financial terms of were not disclosed. Phillips-Medisize was… Read more . . .
-
Johnson & Johnson has announced that intransal esketamine being developed by its subsidiary Janssen Research & Development has received Breakthrough Therapy Designation from the FDA. According to J&J, the product is in Phase 3 development… Read more . . .
-
Cannabis Science, which recently announced that it would introduce a THC/CBD product for use in nebulizers by asthma/COPD patients, now says that it plans to market a metered dose inhaler called the CBIS MDI Rescue… Read more . . .
-
Johnson & Johnson spinout PrEP Biopharm has announced that former GSK Global Head of Analytical Technologies Anna Slater has joined the company as Head of Chemistry, Manufacturing and Controls. At GSK, Slater had been a… Read more . . .
-
Arch Biopartners has announced that Catalent Inhalation will begin the process of manufacturing its AB569 bactericidal inhalation solution for use in trials of the drug in patients with antibiotic resistant lung infections. The process will… Read more . . .
-
AstraZeneca has announced top-line results from the Phase 3 RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) and CHASE 3 (ChildHood Asthma Safety and Efficacy) studies of the Symbicort budesonide/formoterol fumarate MDI… Read more . . .
-
A Q&A with Kristian Debus and Prashanth Shankara of CD-adapco Q: Doesn’t optimization of drug delivery devices using computer simulation require a lot of time and resources? KD: Actually, these days you can optimize an… Read more . . .
-
Windtree Therapeutics has received $1 million from a Phase 2 Small Business Innovation Research Grant (SBIR) worth up to $2.6 million for a Phase 2b trial of its Aerosurf aerosolized KL4 surfactant in premature infants… Read more . . .
-
Dr. Reddy’s Laboratories has acquired tobramycin inhalation solution from Teva Pharmaceutical Industries as part of the divestiture required by the US Federal Trade Commission (FTC) before Teva could acquire Allergan’s generics business. Teva received FDA… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.